Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Chang, Kwang Yu ^a,b,c   Tsai, Shan Yin ^d   Chen, Shang Hung ^b,e   Tsou, Hsiao Hui ^b   Yen, Chia Jui ^c   Liu, Ko Jiunn ^b   Fang, Hsun Lang ^f   Wu, Hung Chang ^e   Chuang, Bin Fay ^b   Chou, Shao Wen ^b   Tang, Careen K ^g   Liu, Shyun Yeu ^e,h   Lu, Pei Jung ^a   Yen, Ching Yu ^e,i   Chang, Jang Yang ^b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f Min Hwei College of Health Care Management   (Taiwan)

^g GEORGETOWN UNIVERSITY   (United States)

^h NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

ⁱ TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AKT; EGFR; EGFRvIII; Oral cancer; PI3K; PTEN

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR VIII;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COPY NUMBER VARIATION; DNA SEQUENCE; ENZYME ACTIVE SITE; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; NUCLEIC ACID BASE SUBSTITUTION; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; GENETICS; METABOLISM; MIDDLE AGED; MOUTH TUMOR; MUTATION; PHOSPHORYLATION;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84879456417     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-43     Document Type: Article

References (53)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Department of Health, Cancer registry annual report in Taiwan area, 2008 Taipei: The Executive Yuan, ROC 2011
3. Betel quid chewing, cigarette smoking, and alcohol consumption related to oral cancer in Taiwan. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC, J Oral Pathol Med 1995 24 450 453 10.1111/j.1600-0714.1995.tb01132.x 8600280
4. The induction of prostaglandin E2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation. Chang MC, Wu HL, Lee JJ, Lee PH, Chang HH, Hahn LJ, Lin BR, Chen YJ, Jeng JH, J Biol Chem 2004 279 50676 50683 10.1074/jbc.M404465200 15375172 (Pubitemid 40017804)
5. The precancer risk of betel quid chewing, tobacco use and alcohol consumption in oral leukoplakia and oral submucous fibrosis in southern Taiwan. Lee CH, Ko YC, Huang HL, Chao YY, Tsai CC, Shieh TY, Lin LM, Br J Cancer 2003 88 366 372 10.1038/sj.bjc.6600727 12569378 (Pubitemid 36308146)
6. EGFR antagonists in cancer treatment. Ciardiello F, Tortora G, N Engl J Med 2008 358 1160 1174 10.1056/NEJMra0707704 18337605 (Pubitemid 351398490)
7. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Grandis JR, Tweardy DJ, Cancer Res 1993 53 3579 3584 8339264 (Pubitemid 23229640)
8. Platinum-based chemotherapy plus cetuximab in head and neck cancer. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R, N Engl J Med 2008 359 1116 1127 10.1056/NEJMoa0802656 18784101
9. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK, N Engl J Med 2006 354 567 578 10.1056/NEJMoa053422 16467544 (Pubitemid 43209104)
10. Targeted therapies in squamous cell carcinoma of the head and neck. Gold KA, Lee HY, Kim ES, Cancer 2009 115 922 935 10.1002/cncr.24123 19156911
11. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR, Clin Cancer Res 2006 12 5064 5073 10.1158/1078-0432.CCR-06-0913 16951222 (Pubitemid 44453332)
12. Oncogenic EGFR signaling networks in glioma. Huang PH, Xu AM, White FM, Sci Signal 2009 2 e6 10.1126/scisignal.287re6 19738203
13. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas. Chiang WF, Liu SY, Yen CY, Lin CN, Chen YC, Lin SC, Chang KW, Oral Oncol 2008 44 270 276 10.1016/j.oraloncology.2007.02.008 17468034 (Pubitemid 351255592)
14. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, Gonzalez MV, Int J Cancer 2005 114 242 248 10.1002/ijc.20711 15543611 (Pubitemid 40194293)
15. PIK3CA mutations in head and neck squamous cell carcinoma. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP, Su GH, Clin Cancer Res 2006 12 1441 1446 10.1158/1078-0432.CCR-05-2173 16533766
16. Expression of phosphorylated Akt in oral carcinogenesis and its induction by nicotine and alkaline stimulation. Wu HT, Ko SY, Fong JH, Chang KW, Liu TY, Kao SY, J Oral Pathol Med 2009 38 206 213 18331557
17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, American Joint Committee on Cancer Staging Manual New York: Springer 7 2009
18. Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. Yu H, Gong X, Luo X, Han W, Hong G, Singh B, Tang CK, Cancer Biol Ther 2008 7 1818 1828 10.4161/cbt.7.11.6847 18787418
19. High Frequency of Mutations of the PIK3CA Gene in Human Cancers. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE, Science 2004 304 554 10.1126/science.1096502 15016963 (Pubitemid 38541907)
20. Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Qiu W, Tong GX, Manolidis S, Close LG, Assaad AM, Su GH, Int J Cancer 2008 122 1189 1194 17990317 (Pubitemid 351214020)
21. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Yatabe Y, Takahashi T, Mitsudomi T, Cancer Res 2008 68 2106 2111 10.1158/0008-5472.CAN-07- 5211 18381415 (Pubitemid 351521782)
22. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
23. PIK3CA mutations and copy number gains in human lung cancers. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF, Cancer Res 2008 68 6913 6921 10.1158/0008-5472.CAN-07-5084 18757405
24. Lang TA, Secic M, How to Report Statistics in Medicine Annotated Guidelines for Authors Editors and Reviewers Philadelphia: American College of Physicians 2 2006
25. EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. Nakata Y, Uzawa N, Takahashi K, Sumino J, Michikawa C, Sato H, Sonoda I, Ohyama Y, Okada N, Amagasa T, Eur J Cancer 2011 47 2364 2372 10.1016/j.ejca.2011.07.006 21852109
26. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L, J Clin Oncol 2007 25 2164 2170 10.1200/JCO.2006.06.6605 17538160 (Pubitemid 46954638)
27. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Wheeler S, Siwak DR, Chai R, Lavalle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM, Clin Cancer Res 2012 18 2278 2289 10.1158/1078-0432.CCR-11-1593 22351687
28. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD, Cell Growth Differ 1995 6 1251 1259 8845302
29. Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. Del Vecchio CA, Jensen KC, Nitta RT, Shain AH, Giacomini CP, Wong AJ, Cancer Res 2012 72 2657 2671 10.1158/0008-5472.CAN-11-2656 22419663
30. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM, Collins VP, J Mol Med (Berl) 2005 83 917 926 10.1007/s00109-005-0700-2 (Pubitemid 41598692)
31. Phase II trial of gefitinib in recurrent glioblastoma. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE II, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS, J Clin Oncol 2004 22 133 142 14638850 (Pubitemid 41095125)
32. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y, Cancer Res 2003 63 6962 6970 14583498 (Pubitemid 37322983)
33. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K, Clin Cancer Res 2005 11 1462 1466 10.1158/1078-0432.CCR-04-1737 15746047 (Pubitemid 40315227)
34. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K, J Clin Oncol 2007 25 2288 2294 10.1200/JCO.2006.08.0705 17538175 (Pubitemid 46954657)
35. The association between EGFR variant III, HPV, p16, c-MET,EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, Zhang T, Ludkovski O, Wang L, Chen EX, Tsao MS, Kamel-Reid S, Siu LL, Head Neck Oncol 2011 3 11 10.1186/1758-3284-3-11 21352589
36. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Ge H, Gong X, Tang CK, Int J Cancer 2002 98 357 361 10.1002/ijc.10224 11920586 (Pubitemid 34188678)
37. Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer. Keller J, Shroyer KR, Batajoo SK, Zhao HL, Dong LM, Hayman MJ, Chan EL, Cancer Invest 2010 28 1054 1062 10.3109/07357907.2010.512602 20873989
38. Altered subcellular location of an activated and tumor-associated epidermal growth factor receptor. Ekstrand AJ, Liu L, He J, Hamid ML, Longo N, Collins VP, James CD, Oncogene 1995 10 1455 1460 7731699
39. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Han W, Zhang T, Yu H, Foulke JG, Tang CK, Cancer Biol Ther 2006 5 1361 1368 10.4161/cbt.5.10.3226 16969069 (Pubitemid 44772265)
40. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee WK, Scott AM, Mischel PS, Hoogenraad NJ, Johns TG, J Cell Sci 2011 124 2938 2950 10.1242/jcs.083295 21878501
41. EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study. Bernardes VF, Gleber-Netto FO, Sousa SF, Rocha RM, Aguiar MC, BMJ Open 2013 3 002077 10.1136/bmjopen-2012-002077 23358562
42. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K, Buerger H, Clin Cancer Res 2006 12 7252 7260 10.1158/1078-0432.CCR-06-0626 17189396 (Pubitemid 46095396)
43. The molecular biology of head and neck cancer. Leemans CR, Braakhuis BJ, Brakenhoff RH, Nat Rev Cancer 2011 11 9 22 10.1038/nrc2982 21160525
44. Copy number amplification of 3q26-27 oncogenes in microdissected oral squamous cell carcinoma and oral brushed samples from areca chewers. Lin SC, Liu CJ, Ko SY, Chang HC, Liu TY, Chang KW, J Pathol 2005 206 417 422 10.1002/path.1790 15906274 (Pubitemid 41025344)
45. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, Inazawa J, Cancer Sci 2006 97 1351 1358 10.1111/j.1349-7006.2006.00343. x 17052259 (Pubitemid 44614987)
46. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ, J Biol Chem 1998 273 200 206 10.1074/jbc.273.1.200 9417065 (Pubitemid 28042194)
47. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, Depinho RA, Bonni A, Genes Dev 2008 22 449 462 10.1101/gad.1606508 18258752 (Pubitemid 351272753)
48. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Lo HW, Cao X, Zhu H, Ali-Osman F, Mol Cancer Res 2010 8 232 245 10.1158/1541-7786.MCR-09-0391 20145033
49. EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. Rahimi M, George J, Tang C, Int J Cancer 2010 126 1850 1860 19830694
50. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM, Cancer Res 2008 68 1953 1961 10.1158/0008-5472.CAN-07-5659 18339877 (Pubitemid 351416582)
51. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM, Oncogene 2008 27 3944 3956 10.1038/onc.2008.19 18297114 (Pubitemid 351913636)
52. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY, Clin Cancer Res 2011 17 7116 7126 10.1158/1078-0432.CCR-11-0796 21976531
53. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD, J Clin Oncol 2010 28 4722 4729 10.1200/JCO.2010.28.6963 20921459